ACM
TARS icon

Accent Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Accent Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-85
Closed -$6.96K – 379
2025
Q4 		$6.96K Buy
+85
New +$6.35K ﹤0.01% 250
2025
Q3 		– Sell
-105
Closed -$4.25K – 426
2025
Q2 		$4.25K Hold
105
– – ﹤0.01% 343
2025
Q1 		$5.39K Hold
105
– – ﹤0.01% 241
2024
Q4 		$5.81K Buy
+105
New +$4.77K ﹤0.01% 164

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Accent Capital Management's TARS Position: Q1 2026 in Review

Accent Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 85 shares — an estimated $6.96K sold.

Accent Capital Management first reported a position in TARS in Q4 2024 and held it in 4 quarters. The position peaked at $6.96K in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Accent Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Accent Capital Management sold 85 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $6.96K.
  • Accent Capital Management first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Accent Capital Management's Tarsus Pharmaceuticals position peaked at $6.96K in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Accent Capital Management's 13F filing for Q1 2026, filed 11 May 2026.